Relmada Therapeutics (RLMD) Tops Q1 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.87), $0.03 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
• Endava CFO placed on leave amid accounting probe